274 related articles for article (PubMed ID: 32342914)
1. The Association Between Clinicopathological Features and Molecular Markers in Bahraini Women With Breast Cancer.
AlZaman A; Ali E; Mohamad B; Islam M; AlZaman E; AlZaman Y
Gulf J Oncolog; 2020 Jan; 1(32):19-25. PubMed ID: 32342914
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
5. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.
Elidrissi Errahhali M; Elidrissi Errahhali M; Ouarzane M; El Harroudi T; Afqir S; Bellaoui M
BMC Womens Health; 2017 Jan; 17(1):3. PubMed ID: 28068979
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of indonesian breast cancers with different molecular subtypes.
Widodo I; Dwianingsih EK; Triningsih E; Utoro T; Soeripto
Asian Pac J Cancer Prev; 2014; 15(15):6109-13. PubMed ID: 25124582
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Features of Triple Negative Breast Carcinoma.
Reddy GM; Suresh PK; Pai RR
J Clin Diagn Res; 2017 Jan; 11(1):EC05-EC08. PubMed ID: 28273970
[TBL] [Abstract][Full Text] [Related]
8. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain.
AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES
Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972
[TBL] [Abstract][Full Text] [Related]
9. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
[TBL] [Abstract][Full Text] [Related]
10. A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India.
Somal PK; Sancheti S; Sharma A; Sali AP; Chaudhary D; Goel A; Dora TK; Brar R; Gulia A; Divatia J
South Asian J Cancer; 2023 Apr; 12(2):104-111. PubMed ID: 37969672
[TBL] [Abstract][Full Text] [Related]
11. Clinical risk analysis of non-visualized sentinel lymph node in breast cancer.
Zhang J; Pei J; Liu H
Cancer Biomark; 2018; 23(2):179-183. PubMed ID: 30198862
[TBL] [Abstract][Full Text] [Related]
12. Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study.
Agresti R; Meneghini E; Baili P; Minicozzi P; Turco A; Cavallo I; Funaro F; Amash H; Berrino F; Tagliabue E; Sant M
Breast Cancer Res Treat; 2016 May; 157(1):179-89. PubMed ID: 27117160
[TBL] [Abstract][Full Text] [Related]
13. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
14. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
15. Association between molecular subtypes and lymph node status in invasive breast cancer.
Si C; Jin Y; Wang H; Zou Q
Int J Clin Exp Pathol; 2014; 7(10):6800-6. PubMed ID: 25400761
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
19. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of prolactin receptor expression in breast cancer subtypes].
Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
